Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069941 | 0.95 | HTR1A (0.33) | DRD2DRD3LMNAHTR1AMAPT | |
| SCHEMBL4060191 | 0.89 | DRD2 (0.30) | DRD2 | |
| SCHEMBL4361438 | 0.85 | MAPT (0.37) | DRD2DRD3LMNAHTR1AMAPT | |
| SCHEMBL11897301 | 0.85 | MAPT (0.37) | DRD2DRD3LMNAHTR1AMAPT | |
| SCHEMBL4059963 | 0.85 | CSNK2A2 (0.31) | — | |
| SCHEMBL4062174 | 0.85 | CSNK2A2 (0.31) | — | |
| SCHEMBL4066930 | 0.85 | — | — | |
| SCHEMBL4062217 | 0.82 | CSNK2A2 (0.33) | DRD2DRD3LMNAMAPT | |
| SCHEMBL14101115 | 0.82 | MAPK1 (0.38) | DRD2DRD3LMNAHTR1A | |
| SCHEMBL31374750 | 0.82 | DRD2 (0.45) | DRD2DRD3LMNAHTR1AGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | claimed |
| US-20260055216-A1 | Conjugated Diene-Based Polymer, Formed Body, Production Method for Conjugated Diene-Based Polymer, Rubber Composition, and Tire | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-02-26 | — | — | US | disclosed |
| CN-119497723-A | Conjugated diene polymer, molded article, method for producing conjugated diene polymer, rubber composition, and tire | 旭化成株式会社 | 2025-02-21 | — | — | CN | disclosed |
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1714968-B1 | Protected piperazino group-bearing organoxysilane compound and making method | SHINETSU CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| EP-1714968-A1 | Protected piperazino group-bearing organoxysilane compound and making method | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055216-A1 | Conjugated Diene-Based Polymer, Formed Body, Production Method for Conjugated Diene-Based Polymer, Rubber Composition, and Tire | HMGB2, HMGB1, HMGB3 | DRD2 1369/4885DRD3 1082/4885LMNA 1042/4885 |
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | PIEZO1, VCL, VIM | DRD2 2063/4885DRD3 2220/4885LMNA 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.